Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.3
4.3
Journals
Antibiotics
Special Issues
Editorial Board Members' Collection Series: Bridging the Gap: Translational and...
share announcement

Editorial Board Members' Collection Series: Bridging the Gap: Translational and Clinical Approaches on Antibiotic Pharmacokinetics and Pharmacodynamics

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics of Drugs".

Deadline for manuscript submissions: closed (31 May 2024) | Viewed by 3765

Special Issue Editors

Dr. Antonello Di Paolo

E-Mail Website
Guest Editor
Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, 56126 Pisa, Italy
Interests: pharmacokinetics; pharmacometrics; antibacterial drugs; intensive care units; therapeutic drug monitoring
Special Issues, Collections and Topics in MDPI journals
Dr. Dominique Breilh

E-Mail Website
Guest Editor
Centre Hospitalier Universitaire de Bordeauxd, Talence, France
Interests: antibiotics; PKPD

Special Issue Information

Dear Colleagues,

In the ongoing battle against bacterial infections, optimizing antibiotic use stands as a fundamental objective at the intersection of science and clinical practice. Antibiotic pharmacokinetics and pharmacodynamics (PKs/PDs) are pivotal in determining the efficacy of antibiotic treatments and in addressing the emergence of resistance. The interplay between laboratory research and clinical practice, a fruitful stewardship including different professionals, is a dynamic field that holds promise in enhancing the therapeutic management of infectious diseases.

Within this Special Issue, we encourage the submission of original research, reviews, clinical studies, and interdisciplinary collaborations that delve into antibiotic PK/PD principles. Topics of interest for this Special Issue include the following: in vitro and in vivo studies, dosing strategies, therapeutic drug monitoring, pharmacogenomics, and the application of PK/PD concepts in real-world clinical scenarios. By fostering a scholarly exchange at this intersection, we aim to cultivate a comprehensive understanding of antibiotic pharmacokinetics and pharmacodynamics, thereby promoting evidence-based clinical decision making, improving patient outcomes, and combating the growing menace of antibiotic resistance.

Dr. Antonello Di Paolo
Dr. Dominique Breilh
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacokinetics
  • pharmacodynamics
  • PK/PD
  • antibiotic
  • antimicrobials

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 2379 KiB  
Article
Linezolid Pharmacokinetics in Critically Ill Patients: Continuous Versus Intermittent Infusion
by Ligia-Ancuța Hui, Constantin Bodolea, Adina Popa, Ana-Maria Vlase, Elisabeta Ioana Hirișcău and Laurian Vlase
Antibiotics 2024, 13(10), 961; https://doi.org/10.3390/antibiotics13100961 - 11 Oct 2024
Viewed by 1843
Abstract
Background: Linezolid has been found to have considerable interindividual variability, especially in critically ill patients, which can lead to suboptimal plasma concentration. To overcome this shortcoming, several solutions have been proposed. These include using loading dose, higher maintenance doses, and dose stratification according [...] Read more.
Background: Linezolid has been found to have considerable interindividual variability, especially in critically ill patients, which can lead to suboptimal plasma concentration. To overcome this shortcoming, several solutions have been proposed. These include using loading dose, higher maintenance doses, and dose stratification according to the patient’s particularities, therapeutic drug monitoring, and drug administration via continuous infusion (CI) instead of intermittent infusion (II). In the present study, we aim to compare the pharmacokinetic (PK) parameters of linezolid after administration as II versus CI to critically ill patients. Methods: In a prospective study conducted in an intensive care unit, we compared the same two daily doses of linezolid administered via II versus CI. The serum concentration was measured, and pharmacokinetic parameters were calculated. The pharmacokinetic/pharmacodynamic (PK/PD) indices for efficacy chosen were area under the concentration–time curve at steady state divided by the minimum inhibitory concentration over 80 (AUC24–48/MIC > 80). Results: Greater serum concentration variability was observed in the II group than in the CI group. The %T > MIC > 80% was achieved for MICs of 1 and 2 µg/mL 100% of the time, whereas for the II group, this was 93% and 73%, respectively. AUC24–48/MIC > 80 was reached in 100% of cases in the CI group compared with 87% in the II group for a MIC of 1 µg/mL. Conclusions: The two infusion methods may be used comparably, but utilizing CI as an alternative to II may have potential benefits, including avoiding periods of suboptimal concentrations, which may enhance safety profiles and clinical outcomes. Considering the relatively few studies performed on linezolid to date, which are increasing in number, the results of the present study may be of interest. Full article
(This article belongs to the Special Issue Editorial Board Members' Collection Series: Bridging the Gap: Translational and Clinical Approaches on Antibiotic Pharmacokinetics and Pharmacodynamics)
►▼ Show Figures

Figure 1

10 pages, 915 KiB  
Article
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety
by María Martín-Cerezuela, Cristina Maya Gallegos, María Remedios Marqués-Miñana, María Jesús Broch Porcar, Andrés Cruz-Sánchez, Juan Carlos Mateo-Pardo, José Esteban Peris Ribera, Ricardo Gimeno, Álvaro Castellanos-Ortega, José Luis Poveda Andrés and Paula Ramírez Galleymore
Antibiotics 2024, 13(8), 706; https://doi.org/10.3390/antibiotics13080706 - 29 Jul 2024
Cited by 1 | Viewed by 1550
Abstract
Isavuconazole is used to treat fungal infections. This study aims to describe isavuconazole pharmacokinetics in critically ill patients and evaluate their relationship with clinical efficacy and patient safety. We conducted a prospective, observational study in patients treated with intravenous isavuconazole. Samples were collected [...] Read more.
Isavuconazole is used to treat fungal infections. This study aims to describe isavuconazole pharmacokinetics in critically ill patients and evaluate their relationship with clinical efficacy and patient safety. We conducted a prospective, observational study in patients treated with intravenous isavuconazole. Samples were collected at predose (Cmin), 1 h (Cmax) and 12 h (C50) after the last dose. The plasma concentration was determined by high-performance liquid chromatography. The relationship between plasma concentration and clinical and microbiological outcomes and safety was evaluated. The influence of covariates (age, sex, weight, SAPS3, creatinine, liver enzymes and extracorporeal devices: continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO)) was analysed. Population pharmacokinetic modelling was performed using NONMEN®. A total of 71 isavuconazole samples from 24 patients were analysed. The mean Cmin was 1.76 (1.02) mg/L; 87.5% reached the optimal therapeutic target and 12.5% were below 1 mg/L. Population pharmacokinetics were best described by a one-compartment model with first-order elimination. No factor had a significant impact on the plasma concentration or pharmacokinetic parameters. Thus, isavuconazole could be safely used in a critically ill population, even in those treated with CRRT and ECMO, from a pharmacokinetic standpoint. Therefore, routine therapeutic drug monitoring may not be strictly necessary in daily clinical practice. Full article
(This article belongs to the Special Issue Editorial Board Members' Collection Series: Bridging the Gap: Translational and Clinical Approaches on Antibiotic Pharmacokinetics and Pharmacodynamics)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop